These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26994002)

  • 21. Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.
    Carlo-Stella C; Locatelli SL; Giacomini A; Cleris L; Saba E; Righi M; Guidetti A; Gianni AM
    PLoS One; 2013; 8(4):e61603. PubMed ID: 23620775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer.
    Dadu R; Waguespack SG; Sherman SI; Hu MI; Busaidy NL; Jimenez C; Habra MA; Ying AK; Bassett RL; Cabanillas ME
    Oncologist; 2014 May; 19(5):477-82. PubMed ID: 24733667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
    Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma.
    Blair HA; Plosker GL
    Target Oncol; 2015 Mar; 10(1):171-8. PubMed ID: 25742918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.
    Wilson L; Huang W; Chen L; Ting J; Cao V
    Thyroid; 2017 Aug; 27(8):1043-1052. PubMed ID: 28486081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer.
    Brose MS; Nutting CM; Sherman SI; Shong YK; Smit JW; Reike G; Chung J; Kalmus J; Kappeler C; Schlumberger M
    BMC Cancer; 2011 Aug; 11():349. PubMed ID: 21834960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
    Wang H; Quan H; Lou L
    Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION Trial.
    Brose MS; Schlumbeger M; Jeffers M; Kappeler C; Meinhardt G; Peña CEA
    Clin Cancer Res; 2019 Dec; 25(24):7370-7380. PubMed ID: 31558473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
    Brose MS; Nutting CM; Jarzab B; Elisei R; Siena S; Bastholt L; de la Fouchardiere C; Pacini F; Paschke R; Shong YK; Sherman SI; Smit JW; Chung J; Kappeler C; Peña C; Molnár I; Schlumberger MJ;
    Lancet; 2014 Jul; 384(9940):319-28. PubMed ID: 24768112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.
    Savvides P; Nagaiah G; Lavertu P; Fu P; Wright JJ; Chapman R; Wasman J; Dowlati A; Remick SC
    Thyroid; 2013 May; 23(5):600-4. PubMed ID: 23113752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sorafenib and thyroid cancer.
    Fallahi P; Ferrari SM; Santini F; Corrado A; Materazzi G; Ulisse S; Miccoli P; Antonelli A
    BioDrugs; 2013 Dec; 27(6):615-28. PubMed ID: 23818056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. State of the Art in the Current Management and Future Directions of Targeted Therapy for Differentiated Thyroid Cancer.
    Silaghi H; Lozovanu V; Georgescu CE; Pop C; Nasui BA; Cătoi AF; Silaghi CA
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408830
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
    de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
    Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients.
    Gruber JJ; Colevas AD
    Oncologist; 2015 Feb; 20(2):113-26. PubMed ID: 25616432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib.
    Chen D; Zhao P; Li SQ; Xiao WK; Yin XY; Peng BG; Liang LJ
    Eur J Surg Oncol; 2013 Sep; 39(9):974-80. PubMed ID: 23845703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer.
    Koehler VF; Berg E; Adam P; Weber GL; Pfestroff A; Luster M; Kutsch JM; Lapa C; Sandner B; Rayes N; Fuss CT; Kreissl MC; Hoster E; Allelein S; Schott M; Todica A; Fassnacht M; Kroiss M; Spitzweg C
    Thyroid; 2021 Oct; 31(10):1531-1541. PubMed ID: 34405734
    [No Abstract]   [Full Text] [Related]  

  • 37. Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment.
    Negri FV; Dal Bello B; Porta C; Campanini N; Rossi S; Tinelli C; Poggi G; Missale G; Fanello S; Salvagni S; Ardizzoni A; Maria SE
    Liver Int; 2015 Aug; 35(8):2001-8. PubMed ID: 25559745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice.
    Molina-Vega M; García-Alemán J; Sebastián-Ochoa A; Mancha-Doblas I; Trigo-Pérez JM; Tinahones-Madueño F
    Endocrine; 2018 Feb; 59(2):395-401. PubMed ID: 29275532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort.
    Azad N; Yu M; Davidson B; Choyke P; Chen CC; Wood BJ; Venkatesan A; Henning R; Calvo K; Minasian L; Edelman DC; Meltzer P; Steinberg SM; Annunziata CM; Kohn EC
    Mol Cell Proteomics; 2013 Jun; 12(6):1621-31. PubMed ID: 23449826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias.
    Mirantes C; Dosil MA; Eritja N; Felip I; Gatius S; Santacana M; Matias-Guiu X; Dolcet X
    Eur J Cancer; 2016 Aug; 63():74-87. PubMed ID: 27288872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.